Shineco (SISI) Ignites Growth: $8.7M Tech Deal & Major Singapore Alliance Unleash Dual Engines

BEIJING, Sept. 12, 2025 /PRNewswire/ -- Shineco Inc. (NASDAQ: SISI) ("Shineco" or the "Company"), a developer and commercializer of induced pluripotent stem cell (iPSC) technology platforms, today announced two major strategic advances. Its subsidiary, Xi'an Dong'ao Health Management Co., Ltd. ("Dong'ao Health"), has signed a technology services contract valued at US$8.7 million with Xinke Future Biotechnology (Bazhou) Co., Ltd. for the research and development of "microalgae-derived extracellular vesicles" technology. Separately, a delegation from Singapore's leading biotechnology company, BICC, completed a productive site visit to Dong'ao Health on September 10. The parties reached a broad consensus on key collaboration areas, including establishing a joint laboratory and a technology exchange mechanism, marking a substantive step forward in Shineco's "technology industrialization and global synergy" strategy in the biocellular field.

Read more at prnewswire.com